Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells
- PMID: 3805274
- PMCID: PMC424079
- DOI: 10.1172/JCI112823
Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells
Abstract
The role of membrane transport in the cellular accumulation of 1-beta-D-arabinofuranosylcytosine (ara-C) was studied in freshly isolated human acute leukemia cells. Patient cells had low rates for ara-C transport as compared with human and murine experimental cells and correspondingly low binding capacities for the nucleoside transport inhibitor, nitrobenzylmercaptopurine riboside (NBMPR). At 1 microM ara-C, the rate of net cellular accumulation was close to the membrane transport rate, and NBMPR inhibited transport and accumulation to the same extent. The rate of ara-C accumulation was half maximal at only 3-5 microM, a level much lower than that required for murine cells (67-85 microM). At concentrations below 1 microM the rate of ara-C accumulation was determined primarily by the transport rate, but at higher concentrations above 10 microM, phosphorylation capacity was the principal determinant of the net uptake rate. This difference in the role of transport at high and low ara-C concentrations may explain, in part, the efficacy of high-dose ara-C in patients refractory to standard dose protocols.
Similar articles
-
Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.Cancer Res. 1985 Jul;45(7):3070-5. Cancer Res. 1985. PMID: 4005845
-
Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.Jpn J Cancer Res. 1987 Aug;78(8):851-7. Jpn J Cancer Res. 1987. PMID: 3115933
-
Membrane transport of 1-beta-D-arabinofuranosylcytosine and accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine.Leuk Res. 1991;15(4):255-62. doi: 10.1016/0145-2126(91)90128-g. Leuk Res. 1991. PMID: 2030607
-
Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation.Semin Oncol. 1985 Jun;12(2 Suppl 3):65-74. Semin Oncol. 1985. PMID: 3892704 Review. No abstract available.
-
[Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].Gan To Kagaku Ryoho. 1982 Aug;9(8):1339-51. Gan To Kagaku Ryoho. 1982. PMID: 6191711 Review. Japanese.
Cited by
-
Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.Cancer Chemother Pharmacol. 1992;29(6):455-60. doi: 10.1007/BF00684847. Cancer Chemother Pharmacol. 1992. PMID: 1568288
-
Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.Clin Pharmacokinet. 2000 Jul;39(1):5-26. doi: 10.2165/00003088-200039010-00002. Clin Pharmacokinet. 2000. PMID: 10926348 Review.
-
Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):761-775. doi: 10.1007/s13318-022-00786-5. Epub 2022 Aug 1. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35915365 Review.
-
Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole.Cancer Chemother Pharmacol. 1992;29(3):236-40. doi: 10.1007/BF00686258. Cancer Chemother Pharmacol. 1992. PMID: 1733557
-
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.Ann Hematol. 1991 Apr;62(4):119-28. doi: 10.1007/BF01702925. Ann Hematol. 1991. PMID: 2031974 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical